Pregnancy complications affect approximately 25% of pregnancies, with preeclampsia being one of the main causes of maternal and neonatal morbidity.
There is a significant unmet clinical need in obstetrics.
Preeclampsia is a multisystem disorder characterised by new-onset hypertension and organ dysfunction..
The main challenge is not its treatment, but detection in preclinical stages, when intervention can modify the course of the disease.
Nuestra investigación identifica la resistencia a la decidualización endometrial como un mecanismo implicado en el desarrollo de la preeclampsia.
Esta alteración se asocia con:
Estas alteraciones preceden a las manifestaciones clínicas de la preeclampsia y se asocian con señales moleculares tempranas detectables en sangre materna mediante ARNlc.
First-trimester preeclampsia risk assessment based on:
Taken between weeks 9 and 14
Extraction of circulating cell-free RNA from plasma and analysis with massive sequencing (NGS)
Predicción individual de riesgo con modelo predictivo basado en IA
Results to support medical decisions
This approach makes it possible to move from the observation of symptoms to prediction based on molecular biology.
MaiRa allows an early risk assessment:
Early identification of risk makes it possible to:
The combination of:
Makes it possible to expand the model towards:
iPremom is evolving towards a global platform for predictive prenatal diagnosis
Download here all the documentation needed to carry out the test: instructions, request form, and information sheet and informed consent.
Instructions for clinics and sample collection centres
Test request form (TRF)
Information sheet and consent (IC)
The current model is reactive.
MaiRa introduces an approach based on:
Early detection → Preventive intervention → Pregnancy without preeclampsia